Interest in event-driven PrEP among men who have sex with men using daily PrEP in Mexico in 2019–2020: a cross-sectional assessment in a large-scale demonstration project

References

• Aguilera-Mijares, S., Martínez-Dávalos, A., Bautista-Arredondo, S., & Vermandere, H. (2022). The PrEP care continuum among Mexican men who have sex with men and transwomen: A qualitative study. Sexually Transmitted Diseases, 50(80), 512–517. https://doi.org/10.1097/OLQ.0000000000001759
   Google Scholar
• Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., Mcmahan, V., Bushman, L. R., Casapía, M., Sp, P., Instituto, B., & Investigação, D. (2012). Emtricitabine-tenofovir exposure and pre-exposure efficacy in men who have sex with men. Science Translational Medicine, 4(151), 1–17. https://doi.org/10.1126/scitranslmed.3004006
   Google Scholar
• Antoni, G., Tremblay, C., Delaugerre, C., Charreau, I., Cua, E., Castro, R., Raffi, F., Chas, J., Huleux, T., Spire, B., Capitant, C., Meyer, L., & Molina, J. (2020). On-demand PrEP with TDF/FTC remains effective among men who have sex with men with less frequent sexual intercourse. A post-hoc analysis of the ANRS IPERGAY trial. The Lancet HIV, 7(2), 113–120. https://doi.org/10.1016/S2352-3018(19)30341-8
   Google Scholar
• Carneiro, P. B., Rincon, C., & Golub, S. (2021). Predictors of event-driven regimen choice in current PrEP users and sexual behavior characteristics of MSM receiving sexual health services in New York city. AIDS and Behavior, 25(8), 2410–2418. https://doi.org/10.1007/s10461-021-03203-1
   PubMedGoogle Scholar
• CENSIDA. (2022a). 3er trimestre de 2022. Boletín de Atención Integral de Personas Con VIH, 1–41. https://www.gob.mx/cms/uploads/attachment/file/764470/BOLETIN_DAI_TERCER_TRIMESTRE_2022.pdf
   Google Scholar
• CENSIDA. (2022b). Guía de Atención para Otorgar Profilaxis Preexposición. https://www.gob.mx/cms/uploads/attachment/file/704510/GUI_A_DE_ATENCIO_N_PARA_OTORGAR_PROFILAXIS_2022.pdf
   Google Scholar
• Chan, C., Vaccher, S., Fraser, D., Grulich, A. E., Holt, M., Zablotska-Manos, I., Prestage, G. P., & Bavinton, B. R. (2022). Preferences for current and future PrEP modalities among PrEP-experienced gay and bisexual men in Australia. AIDS and Behavior, 26(1), 88–95. https://doi.org/10.1007/s10461-021-03344-3
   PubMed Web of Science ®Google Scholar
• Cornelisse, V. J., Lal, L., Price, B., Ryan, K. E., Bell, C., Owen, L., & Wright, E. J. (2019). Interest in switching to On-demand HIV pre-exposure prophylaxis (PrEP) among Australian users of daily PrEP: An online survey. Open Forum Infectious Diseases, 6(7), 1–5. https://doi.org/10.1093/ofid/ofz287
   Google Scholar
• Coyer, L., van den Elshout, M. A. M., Achterbergh, R. C. A., Matser, A., Schim van der Loeff, M. F., Davidovich, U., de Vries, H. J. C., Prins, M., Hoornenborg, E., & Boyd, A. (2020). Understanding pre-exposure prophylaxis (PrEP) regimen use: Switching and discontinuing daily and event-driven PrEP among men who have sex with men. EClinicalMedicine, 29–30, 100650. https://dx.doi.org/10.1016/j.eclinm.2020.100650
   PubMedGoogle Scholar
• Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., & Goicochea, P. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine, 363(27), 2587–2599. https://doi.org/10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Greenwald, Z. R., Maheu-Grioux, M., Szabo, J., Robin, J. A., Boissonnault, M., Nguyen, V.-K., & Thomas, R. (2019). Cohort profile: l’Actuel pre-exposure prophylaxis (PrEP) cohort study in Montreal, Canada. BMJ Open, 9(6), e028768. https://doi.org/10.1136/bmjopen-2018-028768
   PubMedGoogle Scholar
• Hannaford, A., Lipshie-Williams, M., Starrels, J. L., Arnsten, J. H., Rizzuto, J., Cohen, P., Jacobs, D., & Patel, V. V. (2018). The use of online posts to identify barriers to and facilitators of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men: A comparison to a systematic review of the peer- reviewed literature. AIDS and Behavior, 22(4), 1080–1095. https://doi.org/10.1007/s10461-017-2011-3
   PubMedGoogle Scholar
• Hojilla, C., Marcus, J., Silverberg, J. L., Bradley Hare, M. J., Herbers, C., Hurley, R., Satre, L., Volk, D. D., & E, J. (2020). Early adopters of event-driven human immunodeficiency virus pre-exposure prophylaxis in a large healthcare system in San Francisco. Clinical Infectious Diseases, 71(10), 2710–2712. https://doi.org/10.1093/cid/ciaa474
   PubMedGoogle Scholar
• Hoornenborg, E., Achterbergh, R., Schim van der Loeff, M. F., Davidovich, U., van der Helm, J. J., Hogewoning, A., & van Duijnhoven, Y. (2018). Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: Baseline analysis of a demonstration study in Amsterdam. Journal of the International AIDS Society, 21(3), e25105. https://doi.org/10.1002/jia2.25105
   PubMedGoogle Scholar
• Hoornenborg, E., Krakower, D. S., Prins, M., Mayer, K. H., Israel, B., & Health, F. (2017). Preexposure prophylaxis for men who have sex with men and transgender persons in early adopting countries: A narrative review. Aids (London, England), 31(16), 2179–2191. https://doi.org/10.1097/QAD.0000000000001627
   PubMedGoogle Scholar
• Jongen, V. W., Reyniers, T., Ympa, Z. M., Schim van der Loeff, M., Davidovich, U., Zimmermann, H. M., & Coyer, L. (2021). Choosing event-driven and daily HIV pre-exposure prophylaxis–data from two European PrEP demonstration projects among men who have sex with men. Journal of the International AIDS Society, 24(8), e25768. https://doi.org/10.1002/jia2.25768
   PubMedGoogle Scholar
• Liegeon, G., Antoni, G., Pialoux, G., Capitant, C., Cotte, L., Charreau, I., Tremblay, C., Cua, E., Senneville, E., Raffi, F., & Meyer, L. (2020). Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate–emtricitabine for HIV pre-exposure prophylaxis. Journal of the International AIDS Society, 23(2), e25420. https://doi.org/10.1002/jia2.25420
   PubMedGoogle Scholar
• Macías-González, F., Vermandere, H., Piñeirúa-Menendez, A., & Bautista-Arredondo, S. (2024). How the COVID-19 pandemic and the health system's response reduced HIV testing and increased late diagnoses in Mexico. AIDS, 38(7), 1067–1072. https://dx.doi.org/10.1097/QAD.0000000000003833
   PubMedGoogle Scholar
• Mansergh, G., Kota, K. K., Stephenson, R., Hirshfield, S., & Sullivan, P. (2021). Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities. Journal of the International AIDS Society, 24(1), 1–6. https://doi.org/10.1002/jia2.25664
   Google Scholar
• McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., Mackie, N., Bowman, C., Lacey, C. J., Apea, V., Brady, M., Fox, J., Taylor, S., Antonucci, S., Khoo, S. H., … Gill, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53–60. https://doi.org/10.1016/S0140-6736(15)00056-2
   PubMed Web of Science ®Google Scholar
• Mitchell, K. M., Dimitrov, D., Hughes, J. P., Xia, F., Donnell, D., Amico, K. R., Bokoch, K., Chitwarakorn, A., Bekker, L. G., Holtz, T. H., Mannheimer, S., Grant, R. M., & Boily, M. C. (2018). In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? Aids (London, England), 32(6), 809–818. https://doi.org/10.1097/QAD.0000000000001766
   PubMed Web of Science ®Google Scholar
• Molina, J. M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C., Le Gall, J. M., Cua, E., Pasquet, A., Raffi, F., Pintado, C., Chidiac, C., Chas, J., Charbonneau, P., Delaugerre, C., Suzan-Monti, M., Loze, B., Fonsart, J., … Delfraissy, J. F. (2015). On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. New England Journal of Medicine, 373(23), 2237–2246. https://doi.org/10.1056/NEJMoa1506273
   PubMed Web of Science ®Google Scholar
• Molina, J.-M., Ghosn, J., Assoumou, L., Delaugerre, C., Algarte-Genin, M., Pialoux, G., Katlama, C., Slama, L., Liegeon, G., Beniguel, L., Ohayon, M., Mouhim, H., Goldwirt, L., Spire, B., Loze, B., Surgers, L., Pavie, J., Lourenco, J., Ben-Mechlia, M., … Costagliola, D. (2022). Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. The Lancet HIV, 9(8), e554–e562. https://doi.org/10.1016/S2352-3018(22)00133-3
   PubMedGoogle Scholar
• Newcomb, M., Ryan, D., Hall, C. X., Macapagal, K., & Mustanski, B. (2021). Limited knowledge of, interest in, and eligibility for event-driven PrEP among MSM in two samples in the United States. Journal of the International AIDS Society, 24, 19–20. https://go.gale.com/ps/i.do?id = GALE%7CA656303523&sid = googleScholar&v = 2.1&it = r&linkaccess = abs&issn = 17582652&p = AONE&sw = w&userGroupName = anon∼ea901f5f
   Google Scholar
• Noret, M., Balavoine, S., Pintado, C., Siguier, M., Brun, A., Bauer, R., Loze, B., Leplatois, A., Aslan, A., Moudachirou, K., Delaugerre, C., Rozenbaum, W., & Molina, J. M. (2018). Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: Experience from a hospital-based clinic in France. Aids (London, England), 32(15), 2161–2169. https://doi.org/10.1097/QAD.0000000000001939
   PubMedGoogle Scholar
• Reyniers, T., Nöstlinger, C., Laga, M., De Baetselier, I., Crucitti, T., Wouters, K., Smekens, B., Buyze, J., & Vuylsteke, B. (2018). Choosing between daily and event-driven pre-exposure prophylaxis: Results of a Belgian PrEP demonstration project. JAIDS Journal of Acquired Immune Deficiency Syndromes, 79(2), 186–194. https://doi.org/10.1097/QAI.0000000000001791
   PubMed Web of Science ®Google Scholar
• UNAIDS. (2021). UNAIDS data 2021. https://www.unaids.org/en/resources/documents/2021/2021_unaids_data
   Google Scholar
• UNAIDS. (2022). UNAIDS global AIDS update 2022. https://www.unaids.org/sites/default/files/media_asset/2022-global-aids-update_en.pdf
   Google Scholar
• Vaccher, S. J., Gianacas, C., Templeton, D. J., Poynten, I. M., Haire, B. G., Ooi, C., Foster, R., McNulty, A., Grulich, A. E., & Zablotska, I. B. (2017). Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the prelude demonstration project. Frontiers in Public Health, 5, 1–8. https://doi.org/10.3389/fpubh.2017.00341
   PubMedGoogle Scholar
• van Hoek, A. J., Reitsema, M., Xiridou, M., van Sighem, A., van Benthem, B., Wallinga, J., van Duijnhoven, Y., van der Loeff, M. S., Prins, M., & Hoornenborg, E. (2021). Offering a choice of daily and event-driven preexposure prophylaxis for men who have sex with men in The Netherlands: A cost-effectiveness analysis. Aids (London, England), 35(10), 1677–1682. https://doi.org/10.1097/QAD.0000000000002913
   PubMed Web of Science ®Google Scholar
• Veloso, V. G., Cáceres, C. F., Hoagland, B., Moreira, R. I., Vega-Ramírez, H., Konda, K. A., Leite, I. C., Bautista-Arredondo, S., Vinícius de Lacerda, M., Valdez Madruga, J., Farias, A., Lima, J. N., Zonta, R., Lauria, L., Tamayo, C. V. O., Flores, H. J. S., Santa Cruz, Y. M. C., Aguayo, R. M. M., Cunha, M., … Campos, K. (2023). Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): A prospective, single-arm, open-label, multicentre implementation study.The Lancet HIV, 10(2), e84–e96. https://doi.org/10.1016/S2352-3018(22)00331-9
   PubMedGoogle Scholar
• World Health Organization. (2019). What’s the 2 + 1 + 1? event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: Update to who’s recommendation on oral PrEP (Issue July). https://www.who.int/publications/i/item/what-s-the-2-1-1-event-driven-oral-pre-exposure-prophylaxis-to-prevent-hiv-for-men-who-have-sex-with-men
   Google Scholar
• World Health Organization. (2022). Differentiated and simplified pre-exposure prophylaxis for HIV prevention. https://iris.who.int/bitstream/handle/10665/360861/9789240053694-eng.pdf?sequence = 1
   Google Scholar
• Wu, H.-J., Ku, S. W.-W., Li, C.-W., Ko, N.-Y., Yu, T., Chung, A.-C., & Strong, C. (2021). Factors associated with preferred pre-exposure prophylaxis dosing regimen among men who have sex with men in real-world settings: A mixed-effect model analysis. AIDS and Behavior, 25(1), 249–258. https://doi.org/10.1007/s10461-020-02964-5
   PubMedGoogle Scholar
• Zimmermann, H. M. L., Eekman, S. W., Achterbergh, R. C. A., Schim van der Loeff, M. F., Prins, M., de Vries, H. J. C., Hoornenborg, E., & Davidovich, U. (2019). Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis – a qualitative analysis. Journal of the International AIDS Society, 22(10), e25389. https://doi.org/10.1002/jia2.25389
   PubMedGoogle Scholar